• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brainstorm lands $2.1m Israeli grant for NurOwn stem cell therapy

June 13, 2017 By Sarah Faulkner

BrainStorm Cell TherapeuticsBrainstorm Cell Therapeutics (NSDQ:BCLI) said today that it landed a $2.1 million grant from the Israel Innovation Authority. The funds are slated to support the development of Brainstorm’s NurOwn mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases, including ALS.

This is the 10th year that Brainstorm has won grant support from the Israeli office – between 2007 and 2017, the IIA has given grants totalling nearly $7.5 million in support of NurOwn.

According to the deal, Brainstorm will be required to pay mid-single digit royalties to the IIA based on the products’ sales, up to a total of the cumulative amount of IIA grants that Brainstorm has received plus accumulated interest.

BrainStorm’s CEO Chaim Lebovits, commented, “The Israel Innovation Authority’s support of our NurOwn program provides further validation for the potential of this treatment to help patients suffering from amyotrophic lateral sclerosis,” CEO Chaim Lebovits said in prepared remarks. “The continued financial support for our research and development is an important contribution to our ability to execute on our strategic plans, as we commence a Phase III pivotal trial with NurOwn.”

In February, the company told Reuters that it is seeking early regulatory approval for NurOwn in Canada. Brainstorm inked an agreement with a Canadian non-profit organization, CCRM, that helps to support the development of regenerative medicine. The organization plans to help BrainStorm meet Canadian regulatory requirements for the early access pathway, which would speed up the treatment’s review process.

If NurOwn qualifies for the rapid review pathway, it could be authorized for distribution in Canada by the beginning of next year, BrainStorm told the news outlet.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Featured, Funding Roundup, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS